This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
by Zacks Equity Research
Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
by Moumi Mondal
TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
by Zacks Equity Research
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
Verastem Oncology to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 earnings.
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
by Kinjel Shah
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
by Zacks Equity Research
Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise.
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
by Zacks Equity Research
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
by Zacks Equity Research
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
by Zacks Equity Research
Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have boosted sales in the second quarter of 2023 amid severe competition and pricing pressure in the United States.
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.69% and 33.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.
Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA
by Zacks Equity Research
The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.
Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC
by Zacks Equity Research
Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.
Verastem (VSTM) Enters Overbought Territory
by Zacks Equity Research
Verastem (VSTM) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer
by Zacks Equity Research
Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.
Verastem (VSTM) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
Verastem (VSTM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (VSTM) Outperforming Other Medical Stocks This Year?
Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.